RxDoctor Payments Data

Joseph Sperduto, MD

Internal Medicine · Delray Beach, FLNPI 1386651800

Payments from drug & device makers

$257in general payments, 2019–2025

Across 14 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$73
  • Pfizer$66
  • Novo Nordisk$57
  • Novartis$25
  • AstraZeneca$21
  • Boehringer Ingelheim$15

What the payments were for

  • Food & beverage$24294%
  • Education$156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$257 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$245,105
Medicare patients
699
Services billed
4,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$332,289
EliquisApixaban240$217,854
XareltoRivaroxaban149$167,396
MounjaroTirzepatide134$153,410
JardianceEmpagliflozin82$76,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$44,497
JanuviaSitagliptin Phosphate20$30,491
CreonLipase/Protease/Amylase13$25,070
FarxigaDapagliflozin Propanediol32$24,995
OzempicSemaglutide14$18,804
EntrestoSacubitril/Valsartan18$18,377
LinzessLinaclotide14$15,390
RybelsusSemaglutide13$14,022
TradjentaLinagliptin15$11,591
TrulicityDulaglutide12$11,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$66$222,141268 claims
Boehringer IngelheimJardiance, Tradjenta$15$88,12597 claims
Novo NordiskOzempic, Rybelsus$57$32,82627 claims
AstraZenecaFarxiga$21$24,99532 claims
NovartisEntresto$25$18,37718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →